title: Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection.
abstract: Bacterial superinfections are a primary cause of death during influenza pandemics and epidemics. Type I interferon (IFN) signaling contributes to increased susceptibility of mice to bacterial superinfection around day 7 post-influenza A virus (IAV) infection. Here we demonstrate that the reduced susceptibility to methicillin-resistant Staphylococcus aureus (MRSA) at day 3 post-IAV infection, which we previously reported was due to interleukin-13 (IL-13)/IFN-γ responses, is also dependent on type I IFN signaling and its subsequent requirement for protective IL-13 production. We found, through utilization of blocking antibodies, that reduced susceptibility to MRSA at day 3 post-IAV infection was IFN-β dependent, whereas the increased susceptibility at day 7 was IFN-α dependent. IFN-β signaling early in IAV infection was required for MRSA clearance, whereas IFN-α signaling late in infection was not, though it did mediate increased susceptibility to MRSA at that time. Type I IFN receptor (IFNAR) signaling in CD11c(+) and Ly6G(+) cells was required for the observed reduced susceptibility at day 3 post-IAV infection. Depletion of Ly6G(+) cells in mice in which IFNAR signaling was either blocked or deleted indicated that Ly6G(+) cells were responsible for the IFNAR signaling-dependent susceptibility to MRSA superinfection at day 7 post-IAV infection. Thus, during IAV infection, the temporal differences in type I IFN signaling increased bactericidal activity of both CD11c(+) and Ly6G(+) cells at day 3 and reduced effector function of Ly6G(+) cells at day 7. The temporal differential outcomes induced by IFN-β (day 3) and IFN-α (day 7) signaling through the same IFNAR resulted in differential susceptibility to MRSA at 3 and 7 days post-IAV infection.
  
  
  
  Approximately 114,000 hospitalizations and 40,000 annual deaths in the United States are associated with influenza A virus (IAV) infections. Frequently, these deaths are due to community-acquired Gram-positive bacterial species, many of which show increasing resistance to antibiotic therapy. Severe complications, including parapneumonic empyema and necrotizing pneumonia, can arise, depending on virulence factors expressed by either the virus or bacteria. Unfortunately, we are unable to control the expression of these virulence factors, making host responses a logical target for therapeutic interventions. Moreover, interactions between virus, host, and bacteria that exacerbate IAV-related morbidities and mortalities are largely unknown. Here, we show that type I interferon (IFN) expression can modulate susceptibility to methicillin-resistant Staphylococcus aureus (MRSA) infection, with IFN-β reducing host susceptibility to MRSA infection while IFN-α increases susceptibility. Our data indicate that treatments designed to augment IFN-β and/or inhibit IFN-α production around day 7 post-IAV infection could reduce susceptibility to deadly superinfections.
authors.affiliation: Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
authors.forename: Kelly M
authors.identifier: 0000-0003-3631-2594
authors.initials: KM
authors.lastname: Shepardson
authors.affiliation: Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
authors.forename: Kyle
authors.initials: K
authors.lastname: Larson
authors.affiliation: Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
authors.forename: Rachelle V
authors.initials: RV
authors.lastname: Morton
authors.affiliation: Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
authors.forename: Justin R
authors.initials: JR
authors.lastname: Prigge
authors.affiliation: Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
authors.forename: Edward E
authors.initials: EE
authors.lastname: Schmidt
authors.affiliation: Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, Vermillion, South Dakota, USA.
authors.forename: Victor C
authors.initials: VC
authors.lastname: Huber
authors.affiliation: Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA agnieszka.rynda@montana.edu.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Rynda-Apple
mesh_terms: D000818:Animals; D000950:Antigens, Ly / Q000032:analysis; D039521:CD11c Antigen / Q000032:analysis; D004198:Disease Susceptibility; D006801:Humans; D007251:Influenza, Human / Q000150:complications* / Q000276:immunology; D007370:Interferon Type I / Q000378:metabolism*; D018793:Interleukin-13 / Q000378:metabolism; D007962:Leukocytes / Q000737:chemistry / Q000276:immunology*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000276:immunology*; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D053633:Receptor, Interferon alpha-beta / Q000378:metabolism; D015398:Signal Transduction; D013203:Staphylococcal Infections / Q000276:immunology*; D015163:Superinfection / Q000276:immunology*
chemical_list: D000950:Antigens, Ly; D039521:CD11c Antigen; D007370:Interferon Type I; D018793:Interleukin-13; C480309:Ly6G antigen, mouse; D053633:Receptor, Interferon alpha-beta